PDS Biotechnology
PDSB
48 hedge funds and large institutions have $9.81M invested in PDS Biotechnology in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 12 closing their positions.
15,650% more call options, than puts
Call options by funds: $315K | Put options by funds: $2K
41% more capital invested
Capital invested by funds: $6.94M → $9.81M (+$2.87M)
6.78% more ownership
Funds ownership: 11.37% → 18.15% (+6.8%)
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
8% less funds holding
Funds holding: 52 → 48 (-4)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$6.29M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$286K |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$142K |
| 4 |
IGGA
Iron Gate Global Advisors
Nsl,
Utah
|
+$107K |
| 5 |
VPIM
Vanguard Personalized Indexing Management
Oakland,
California
|
+$40.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$315K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$313K |
| 3 |
Renaissance Technologies
New York
|
-$163K |
| 4 |
Millennium Management
New York
|
-$108K |
| 5 |
Two Sigma Investments
New York
|
-$107K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
51
Virtu Financial
New York
| – | -$89K | -54,693 | Closed |
|
52
Vontobel Holding
Zurich,
Switzerland
| – | -$65.2K | -40,000 | Closed |
|
53
Marshall Wace
London,
United Kingdom
| – | -$63.6K | -39,024 | Closed |
|
54
Jane Street
New York
| – | -$58.1K | -35,644 | Closed |
|
|
XT
55
XTX Topco
George Town,
Cayman Islands
| – | -$40K | -24,535 | Closed |
|
|
SPA
56
Sherbrooke Park Advisers
White Plains,
New York
| – | -$22.9K | -14,026 | Closed |
|
57
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.71K | -1,202 | -81% |
|
|
EWA
58
EverSource Wealth Advisors
Birmingham,
Alabama
| – | -$703 | -431 | Closed |
|
|
RS
59
R Squared
Central,
Hong Kong
| – | -$489 | -300 | Closed |
|
60
Citigroup
New York
| – | -$33 | -20 | Closed |
|
PDSB Hedge Fund Activity: Q1 2025 in Review
48 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2025, worth a combined $9.81M — up 41% from $6.94M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PDSB and 9 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 11 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $6.29M. The largest seller was Susquehanna International Group, cutting an estimated $315K.
- 48 institutional investors held PDS Biotechnology (PDSB) as of Q1 2025, down from 52 in Q4 2024.
- Funds reported $9.81M of PDS Biotechnology stock for Q1 2025, up 41% quarter-over-quarter.
- 9 funds opened new PDS Biotechnology positions in Q1 2025 and 12 closed out, a net change of -3 holders.
- The largest PDS Biotechnology buyer in Q1 2025 was Armistice Capital, an estimated $6.29M added.
- The largest PDS Biotechnology seller in Q1 2025 was Susquehanna International Group, an estimated $315K sold.
Based on aggregated 13F filings for Q1 2025.